Antirheumatic Agents

"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Descriptor ID	D018501
MeSH Number(s)	D27.505.954.329
Concept/Terms	Antirheumatic Agents Antirheumatic Agents Anti-Rheumatic Drugs Anti Rheumatic Drugs Antirheumatic Drugs Anti-Rheumatic Agents Anti Rheumatic Agents Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease Modifying DMARD Disease-Modifying, Antirheumatic Second-Line Drugs Disease Modifying, Antirheumatic Second Line Drugs Antirheumatic Disease-Modifying Second-Line Drugs Antirheumatic Disease Modifying Second Line Drugs Disease-Modifying Antirheumatic Drugs Disease Modifying Antirheumatic Drugs Anti-Rheumatic Agents, Non-Steroidal Anti-Rheumatic Agents, Non-Steroidal Anti Rheumatic Agents, Non Steroidal Non-Steroidal Anti-Rheumatic Agents

Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antirheumatic Agents [D27.505.954.329]

Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.

Bar chart showing 178 publications over 26 distinct years, with a maximum of 16 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	1	0	1
2002	1	0	1
2003	1	2	3
2005	1	0	1
2006	2	1	3
2007	3	1	4
2008	3	2	5
2009	6	1	7
2010	4	2	6
2011	3	3	6
2012	10	3	13
2013	13	0	13
2014	5	2	7
2015	13	2	15
2016	12	1	13
2017	11	1	12
2018	9	1	10
2019	10	6	16
2020	6	2	8
2021	3	1	4
2022	6	0	6
2023	6	0	6
2024	9	0	9
2025	6	1	7
2026	1	0	1

Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.

Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess LJ, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Kristen Demoruelle M, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026 Apr; 78(4):809-820.

View in: PubMed
Paudel ML, Shadick N, Weinblatt M, Reed G, Litman HJ, Kremer JM, Pappas DA, Solomon DH. Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients. Arthritis Care Res (Hoboken). 2026 Jan; 78(1):54-65.

View in: PubMed
Moon SM, Han K, Jung JH, Park J, Yang B, Eun Y, Choi H, Kim H, Shin DW, Lee H. Risk of pneumonia in individuals with rheumatoid arthritis: a nationwide cohort study. BMJ Open Respir Res. 2025 Sep 25; 12(1).

View in: PubMed
Choi H, Han K, Jung JH, De Soyza A, Kim H, Shin DW, Lee H. Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis. Ther Adv Respir Dis. 2025 Jan-Dec; 19:17534666251360071.

View in: PubMed
Litman HJ, Sheffield KM, Pugach O, Shan M, Lakin P, Cui ZL, Curtis SE, Johnston JA, Harrold LR. Applying Bias Correction Methods to Build Hybrid Controls Using Real-World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis. Pharm Stat. 2025 Jul-Aug; 24(4):e70020.

View in: PubMed
Avouac J, Kay J, Choy E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges. Semin Arthritis Rheum. 2025 Aug; 73:152740.

View in: PubMed
Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE, Crow MK, Kay J, Crofford L, Baraliakos X, Bykerk V, Siebert S, Kloppenburg M, Aletaha D, McInnes IB, Huizinga T, Voll R, Gravallese EM, Breedveld FC, van Vollenhoven R, Smolen JS. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis. 2025 Jun; 84(6):927-936.

View in: PubMed
Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 2025 Mar 19; 26(1):96.

View in: PubMed
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.

View in: PubMed
Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.

View in: PubMed

People

Explore

Similar Concepts

Top Journals